

# Phil F Cheng

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8588895/phil-f-cheng-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77  
papers

2,071  
citations

24  
h-index

43  
g-index

92  
ext. papers

2,870  
ext. citations

8  
avg, IF

4.7  
L-index

#	Paper	IF	Citations
77	Mycobacterial infection aggravates Helicobacter pylori-induced gastric preneoplastic pathology by redirection of de novo induced Treg cells.. <i>Cell Reports</i> , <b>2022</b> , 38, 110359	10.6	0
76	Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 793992	8.4	0
75	568 Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment <b>2021</b> , 9, A597-A597		
74	Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression. <i>Cancer Research</i> , <b>2021</b> , 81, 6044-6057	10.1	3
73	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. <i>Nature Communications</i> , <b>2021</b> , 12, 1434	17.4	5
72	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. <i>European Journal of Cancer</i> , <b>2021</b> , 149, 37-48	7.5	3
71	IL-6 blockade for prophylaxis and management of immune-related adverse events (irAEs) with anti-PD-1 based immunotherapy.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 9553-9553	2.2	0
70	Prolonged Unfrozen Storage and Repeated Freeze-Thawing of SARS-CoV-2 Patient Samples Have Minor Effects on SARS-CoV-2 Detectability by RT-PCR. <i>Journal of Molecular Diagnostics</i> , <b>2021</b> , 23, 691-697	5.1	8
69	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
68	A Comparative Study of Real-Time RT-PCR-Based SARS-CoV-2 Detection Methods and Its Application to Human-Derived and Surface Swabbed Material. <i>Journal of Molecular Diagnostics</i> , <b>2021</b> , 23, 796-804	5.1	6
67	NRAS melanoma tumor formation is reduced by p38-MAPK14 activation in zebrafish models and NRAS-mutated human melanoma cells. <i>Pigment Cell and Melanoma Research</i> , <b>2021</b> , 34, 150-162	4.5	3
66	Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4. <i>Nature Communications</i> , <b>2021</b> , 12, 5056	17.4	1
65	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. <i>European Journal of Cancer</i> , <b>2021</b> , 156, 149-163	7.5	2
64	MITF reprograms the extracellular matrix and focal adhesion in melanoma. <i>ELife</i> , <b>2021</b> , 10,	8.9	16
63	Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition. <i>Journal of Investigative Dermatology</i> , <b>2020</b> , 140, 2242-2252.e7	4.3	11
62	The role of cyclin D1 and Ki-67 in the development and prognostication of thin melanoma. <i>Histopathology</i> , <b>2020</b> , 77, 460-470	7.3	9
61	The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype. <i>Cancer Research</i> , <b>2020</b> , 80, 2983-2995	10.1	19

60	Targeting complex, adaptive responses in melanoma therapy. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 86, 101997.4	7
59	Lipoconstruct surface topography grating size influences vascularization onset in the dorsal skinfold chamber model. <i>Acta Biomaterialia</i> , <b>2020</b> , 106, 136-144	10.8 2
58	Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis. <i>European Journal of Dermatology</i> , <b>2020</b> , 30, 699-709	0.8 0
57	Inhibition of p38/MK2 Signaling Prevents Vascular Invasion of Melanoma. <i>Journal of Investigative Dermatology</i> , <b>2020</b> , 140, 878-890.e5	4.3 7
56	A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma. <i>Pigment Cell and Melanoma Research</i> , <b>2020</b> , 33, 334-344	4.5 11
55	The ALPK1/TIFA/NF-B axis links a bacterial carcinogen to R-loop-induced replication stress. <i>Nature Communications</i> , <b>2020</b> , 11, 5117	17.4 21
54	Activation of CD8 T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. <i>Cancer Immunology Research</i> , <b>2020</b> , 8, 1114-1121	12.5 7
53	Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. <i>Melanoma Research</i> , <b>2020</b> , 30, 552-561	3.3 2
52	Skin Recovery After Discontinuation of Long-Term Moisturizer Application: A Split-Face Comparison Pilot Study. <i>Dermatology and Therapy</i> , <b>2020</b> , 10, 1371-1382	4
51	Proteomic analysis of human mesenchymal stromal cell secretomes: a systematic comparison of the angiogenic potential. <i>Npj Regenerative Medicine</i> , <b>2019</b> , 4, 8	15.8 73
50	SMAD signaling promotes melanoma metastasis independently of phenotype switching. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 2702-2716	15.9 28
49	Melanoma patients with additional primary cancers: a single-center retrospective analysis. <i>Oncotarget</i> , <b>2019</b> , 10, 3373-3384	3.3 1
48	Proteomic identification of a marker signature for MAPKi resistance in melanoma. <i>EMBO Journal</i> , <b>2019</b> , 38, e95874	13 11
47	Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 77-85	12.5 61
46	The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in BRAF-mutated advanced melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 686-692	4.6 11
45	Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 667-675	4.6 11
44	E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. <i>Cancer Discovery</i> , <b>2018</b> , 8, 568-581	24.4 41
43	Methadone-Not a magic bullet in melanoma therapy. <i>Experimental Dermatology</i> , <b>2018</b> , 27, 694-696	4 5

42	A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma. <i>Neoplasia</i> , <b>2018</b> , 20, 218-225	6.4	18
41	Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , <b>2018</b> , 78, 1308-1320	10.1	109
40	CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17-Mediated Psoriasiform Skin Inflammation In Vivo. <i>Journal of Investigative Dermatology</i> , <b>2018</b> , 138, 2010-2023	4.3	41
39	Small molecule promotes E-catenin citrullination and inhibits Wnt signaling in cancer. <i>Nature Chemical Biology</i> , <b>2018</b> , 14, 94-101	11.7	66
38	Melanoma Immunotherapy: Next-Generation Biomarkers. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 178	5.3	38
37	Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. <i>Molecular Cancer</i> , <b>2018</b> , 17, 59	42.1	41
36	Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases. <i>Clinical Proteomics</i> , <b>2018</b> , 15, 13	5	8
35	Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis. <i>Melanoma Research</i> , <b>2018</b> , 28, 442-450	3.3	8
34	Medical bioinformatics in melanoma. <i>Current Opinion in Oncology</i> , <b>2018</b> , 30, 113-117	4.2	8
33	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. <i>Cell Reports</i> , <b>2018</b> , 25, 3564-3572.e4	10.6	30
32	EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. <i>Cancer Cell</i> , <b>2018</b> , 34, 69-84.e14	24.3	71
31	Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3181-3190	12.9	23
30	Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?. <i>Melanoma Research</i> , <b>2017</b> , 27, 231-237	3.3	11
29	Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. <i>Melanoma Research</i> , <b>2017</b> , 27, 358-368	3.3	14
28	Metastatic melanoma moves on: translational science in the era of personalized medicine. <i>Cancer and Metastasis Reviews</i> , <b>2017</b> , 36, 7-21	9.6	15
27	Sox2 is dispensable for primary melanoma and metastasis formation. <i>Oncogene</i> , <b>2017</b> , 36, 4516-4524	9.2	20
26	low neurotrophin receptor CD271 regulates phenotype switching in melanoma. <i>Nature Communications</i> , <b>2017</b> , 8, 1988	17.4	43
25	Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma. <i>Current Opinion in Oncology</i> , <b>2016</b> , 28, 172-9	4.2	6

24	Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2020-31	12.9	44
23	PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. <i>Oncotarget</i> , <b>2016</b> , 7, 75551-75560	3.3	15
22	Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. <i>Oncotarget</i> , <b>2016</b> , 7, 77163-77174	3.3	39
21	An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 966-978	4	4
20	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. <i>Nature</i> , <b>2016</b> , 532, 250-4	50.4	205
19	Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma. <i>PLoS Genetics</i> , <b>2015</b> , 11, e1004877	6	59
18	profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma. <i>Oncolmmunology</i> , <b>2015</b> , 4, e988458	7.2	7
17	Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 2132-42	6.1	25
16	Loss of Ezh2 promotes a midbrain-to-forebrain identity switch by direct gene derepression and Wnt-dependent regulation. <i>BMC Biology</i> , <b>2015</b> , 13, 103	7.3	21
15	Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma. <i>Journal of Dermatology</i> , <b>2015</b> , 42, 927-8	1.6	
14	Diffuse Cutaneous Melanosis Associated with Malignant Melanoma. <i>Annals of Dermatology</i> , <b>2015</b> , 27, 780-1	0.4	
13	Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139438	3.7	23
12	Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. <i>Genome Biology</i> , <b>2015</b> , 16, 42	18.3	48
11	Transcriptional repression of IFN $\gamma$ by ATF2 confers melanoma resistance to therapy. <i>Oncogene</i> , <b>2015</b> , 34, 5739-48	9.2	14
10	The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. <i>Nature Communications</i> , <b>2015</b> , 6, 6051	17.4	211
9	Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1289-97	12.9	64
8	Data mining The Cancer Genome Atlas in the era of precision cancer medicine. <i>Swiss Medical Weekly</i> , <b>2015</b> , 145, w14183	3.1	27
7	Metastatic melanoma cell lines do not secrete IL-1 $\beta$ but promote IL-1 $\beta$ production from macrophages. <i>Journal of Dermatological Science</i> , <b>2014</b> , 74, 167-9	4.3	11

6	Coexpression of SOX10/CD271 (p75(NTR)) and $\beta$ -Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients. <i>Dermatopathology (Basel, Switzerland)</i> , <b>2014</b> , 1, 35-46	1.9	3
5	Basal cell carcinomas in a tertiary referral centre: a systematic analysis. <i>British Journal of Dermatology</i> , <b>2014</b> , 171, 1066-72	4	24
4	Hypoxia contributes to melanoma heterogeneity by triggering HIF1 $\beta$ -dependent phenotype switching. <i>Journal of Investigative Dermatology</i> , <b>2013</b> , 133, 2436-2443	4.3	97
3	Systematic classification of melanoma cells by phenotype-specific gene expression mapping. <i>Pigment Cell and Melanoma Research</i> , <b>2012</b> , 25, 343-53	4.5	113
2	The possible influence of osmotic poration on cell membrane water permeability. <i>Cryobiology</i> , <b>2009</b> , 58, 62-68	2.7	9
1	Osmoregulatory function of large vacuoles found in notochordal cells of the intervertebral disc running title: an osmoregulatory vacuole. <i>MCB Molecular and Cellular Biomechanics</i> , <b>2007</b> , 4, 227-37	1.2	29